Dr. Kenneth Cusi, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Texas since 1994, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME111806 · TX license J5086 (first issued 1994; cancelled by request)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 67 | 52 |
| Hemoglobin a1c level | 34 | 31 |
| Established patient office or other outpatient visit, 40-54 minutes | 33 | 25 |
| Insertion of needle into vein for collection of blood sample | 16 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pioglitazone Hcl Other prescribers in Gainesville, FL | 12 |
| Jardiance (empagliflozin) Other prescribers in Gainesville, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 26 payments worth $55,535 in total to this clinician.
| Novo Nordisk Inc | $26,963 |
|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12,013 |
| Boehringer Ingelheim International GmbH | $8,300 |
| Eli Lilly and Company | $5,625 |
| GlaxoSmithKline, LLC. | $1,950 |
| Dexcom, Inc. | $684 |
| Consulting Fee | $52,488 |
|---|---|
| Travel and Lodging | $2,013 |
| Speaking at a medical education program | $684 |
| Food and Beverage | $349 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Jun 24, 2025 | Consulting Fee Multiple Therapeutic Areas | $11,250 |
| Novo Nordisk Inc Apr 10, 2025 | Consulting Fee Multiple Therapeutic Areas | $7,950 |
| Eli Lilly and Company Jul 23, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $5,625 |
| Boehringer Ingelheim International GmbH Aug 12, 2025 | Consulting Fee | $4,550 |
| Boehringer Ingelheim International GmbH Jun 20, 2025 | Consulting Fee | $3,750 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 18, 2025 | Consulting Fee | $3,100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 3, 2025 | Consulting Fee | $3,100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 12, 2025 | Consulting Fee | $3,100 |
| Novo Nordisk Inc Jan 8, 2025 | Consulting Fee Multiple Therapeutic Areas | $2,400 |
| GlaxoSmithKline, LLC. Sep 4, 2025 | Consulting Fee | $1,950 |
All 23 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 18, 2025 | Consulting Fee | $388 |
| Novo Nordisk Inc Nov 28, 2025 | Consulting Fee Multiple Therapeutic Areas | $900 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Nov 5, 2025 | Consulting Fee | $1,550 |
| Novo Nordisk Inc Nov 4, 2025 | Consulting Fee Multiple Therapeutic Areas | $900 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 8, 2025 | Consulting Fee | $775 |
| GlaxoSmithKline, LLC. Sep 4, 2025 | Consulting Fee | $1,950 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 3, 2025 | Consulting Fee | $3,100 |
| Boehringer Ingelheim International GmbH Aug 12, 2025 | Consulting Fee | $4,550 |
| Eli Lilly and Company Jul 23, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $5,625 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 18, 2025 | Consulting Fee | $3,100 |
| Novo Nordisk Inc Jun 24, 2025 | Consulting Fee Multiple Therapeutic Areas | $11,250 |
| Novo Nordisk Inc Jun 24, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Denver, CO · in-kind | $685 |
| Novo Nordisk Inc Jun 24, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Denver, CO · in-kind | $507 |
| Novo Nordisk Inc Jun 24, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Denver, CO · in-kind | $112 |
| Novo Nordisk Inc Jun 24, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Denver, CO · in-kind | $28.00 |
| Boehringer Ingelheim International GmbH Jun 20, 2025 | Consulting Fee | $3,750 |
| Dexcom, Inc. May 13, 2025 | Speaking at a medical education program | $684 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 12, 2025 | Consulting Fee | $3,100 |
| Novo Nordisk Inc Apr 10, 2025 | Consulting Fee Multiple Therapeutic Areas | $7,950 |
| Novo Nordisk Inc Apr 10, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Coral Gables, FL · in-kind | $355 |
| Novo Nordisk Inc Apr 10, 2025 | Travel and Lodging Multiple Therapeutic Areas · travel to Coral Gables, FL · in-kind | $327 |
| Novo Nordisk Inc Apr 9, 2025 | Consulting Fee Multiple Therapeutic Areas | $1,200 |
| Novo Nordisk Inc Jan 8, 2025 | Consulting Fee Multiple Therapeutic Areas | $2,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $484,760 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mel…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
Boehringer Ingelheim International GmbH - A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mel…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.